ANEBULO PHARMACEUTICALS, INC. Interest Expense
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Interest Expense of $17.00 thousand for the 3-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. interest expense for the quarter ending 2025-12-31 was $17.00K, a 83.00% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. interest expense for the quarter ending 2025-09-30 was $17.00K, a 83.00% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. interest expense for the quarter ending 2025-06-30 was $300.00K, a 176.58% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. interest expense for the quarter ending 2025-03-31 was $100.00K, a 67.52% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. interest expense for fiscal 2025 was $400.00K, a 100.00% increase from fiscal 2024.
- ANEBULO PHARMACEUTICALS, INC. interest expense for fiscal 2024 was $200.00K.
- ANEBULO PHARMACEUTICALS, INC. interest expense for fiscal 2021 was $11.77K.
| Period end | Interest Expense 2 month | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $17.00K 10-Q · filed 2026-02-12 | $35.00K 10-Q · filed 2026-02-12 | $334.00K derived: sum of 3 quarters · filed 2026-02-12 | $434.00K derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-09-30 | $17.00K 10-Q · filed 2025-11-13 | $317.00K derived: sum of 2 quarters · filed 2025-11-13 | $417.00K derived: sum of 3 quarters · filed 2025-11-13 | $517.00K derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-06-30 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $400.00K derived: sum of 2 quarters · filed 2025-09-29 | $500.00K derived: sum of 3 quarters · filed 2026-02-12 | $400.00K 10-K · filed 2025-09-29 | |
| 2025-03-31 | $100.00K 10-Q · filed 2025-05-13 | $200.00K derived: sum of 2 quarters · filed 2026-02-12 | $100.00K 10-Q · filed 2025-05-13 | $408.47K derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-12-31 | $100.00K 10-Q · filed 2026-02-12 | $100.00K 10-Q · filed 2026-02-12 | $308.47K derived: sum of 3 quarters · filed 2026-02-12 | $368.16K derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-09-30 | $100.00K 10-Q · filed 2025-11-13 | $208.47K derived: sum of 2 quarters · filed 2025-11-13 | $268.16K derived: sum of 3 quarters · filed 2025-11-13 | $300.00K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $108.47K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $168.16K derived: sum of 2 quarters · filed 2025-09-29 | $200.00K derived: sum of 3 quarters · filed 2025-09-29 | $200.00K 10-K · filed 2025-09-29 | |
| 2024-03-31 | $59.70K 10-Q · filed 2024-05-15 | $91.53K derived: sum of 2 quarters · filed 2024-05-15 | $91.53K 10-Q · filed 2024-05-15 | ||
| 2023-12-31 | $31.84K 10-Q · filed 2024-02-13 | $31.84K 10-Q · filed 2024-02-13 | |||
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-09 | $3.70K derived: sum of 2 quarters · filed 2022-09-09 | $11.77K 10-K · filed 2022-09-09 | ||
| 2021-03-31 | $3.70K 10-Q · filed 2021-06-21 | $11.77K 10-Q · filed 2021-06-21 | |||
| 2020-06-30 | $1.29K 10-K · filed 2021-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |